EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Cariprazine Orodispersible Tablet: A New Formulation for Cariprazine

Viktória Meszár, Gabriella Magyar, Gabriella Mészárosné Pásztor, Balázs Szatmári, Krisztina Péter, Lívia Marton, Zsófia B Dombi, Ágota Barabássy

Pharmacopsychiatry · 01.07.2024 · 57 (04) · 180-185

DOI: 10.1055/a-2291-7130 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pharmacopsychiatry, erschienen am 01.07.2024. Verfasst von Viktória Meszár und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Directorate, Gedeon Richter Plc, Budapest, Hungary. Hauptthemen laut MEDLINE: Cross-Over Studies, Therapeutic Equivalency, Tablets, Antipsychotic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IntroductionCariprazine is an atypical dopamine receptor partial agonist antipsychotic available in the form of capsules. Although capsules are one of the most desirable routes of administration, there are certain situations (e. g., in an acute psychiatric setting, or when swallowing difficulties, or liquid shortages are present) when they cannot be administered. Therefore, alternative solutions like orodispersible tablets are needed. This study aimed to investigate the bioequivalence of a newly developed orodispersible tablet to the commercially available hard gelatine capsule of cariprazine 1.5 mg. MethodsThis was a phase I, open-label, randomized, single-dose bioequivalence study. It had a 2-period, 2-sequence, cross-over design, where each subject received one test and one reference product in a randomized sequence, separated by a wash-out period of 55 days. Blood sampling was performed over 72 h after dosing. Cariprazine concentrations were analyzed by a validated HPLC-MS/MS method. Standard bioequivalence statistics was applied to PK parameters calculated by non-compartmental analysis. Safety measures were analyzed descriptively. ResultPharmacokinetic data of 43 healthy volunteers and safety data of 54 subjects was analyzed. Cariprazine AUC0–72h and Cmax geometric mean ratios were 117.76% and 100.88%, respectively. The 90% confidence intervals were within the pre-defined bioequivalence acceptance limits of 80.00% – 125.00%. Safety data was in line with the Summary of Product Characteristics of Cariprazine. Discussion The result of this clinical trial proved the bioequivalence of the new orodispersible tablet formulation when compared to hard gelatine capsules, enabling an alternative option for treatment of those suffering from schizophrenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cross-Over StudiesTherapeutic EquivalencyTabletsAntipsychotic AgentsPiperazinesHumansMaleAdultYoung AdultFemaleAdministration, OralMiddle AgedArea Under CurveCapsules

Substanzen

cariprazineTabletsAntipsychotic AgentsPiperazinesCapsules

Autor:innen und Institutionen

  • Research Directorate, Gedeon Richter Plc, Budapest, Hungary.

Zitieren

APA

Meszár, V., Magyar, G., Pásztor, G. M., Szatmári, B., Péter, K., Marton, L., Dombi, Z. B., & Barabássy, Á. (2024). Cariprazine Orodispersible Tablet: A New Formulation for Cariprazine. Pharmacopsychiatry, 57(04), 180-185. https://doi.org/10.1055/a-2291-7130

Vancouver

Meszár V, Magyar G, Pásztor GM, Szatmári B, Péter K, Marton L, et al. Cariprazine Orodispersible Tablet: A New Formulation for Cariprazine. Pharmacopsychiatry. 2024;57(04):180-185. doi:10.1055/a-2291-7130

BibTeX
@article{Meszr2024,
  author = {Meszár, Viktória and Magyar, Gabriella and Pásztor, Gabriella Mészárosné and Szatmári, Balázs and Péter, Krisztina and Marton, Lívia and Dombi, Zsófia B and Barabássy, Ágota},
  title = {Cariprazine Orodispersible Tablet: A New Formulation for Cariprazine},
  journal = {Pharmacopsychiatry},
  year = {2024},
  volume = {57},
  number = {04},
  pages = {180--185},
  doi = {10.1055/a-2291-7130}
}
Kostenlos starten →